|Articles|August 18, 2005

UT to offer daily reports from Continence Society meeting

Urology Times E-news will roll out a special edition of UT Daily Meeting Report during the upcoming International Continence Society annual meeting in Montreal, Aug. 28 to Sept. 2.

Urology Times E-news will roll out a special edition of UT Daily Meeting Report during the upcoming International Continence Society annual meeting in Montreal, with coverage beginning Aug. 30. Check your e-mail inbox for daily news on stress incontinence, overactive bladder, and more. As a current E-news subscriber, you are automatically signed up to receive the Daily Meeting Report. Your colleagues can register at www.urologytimes.com/enews.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

October 23rd, 2026

Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC

At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.

October 23rd, 2026

Gedatolisib plus darolutamide shows preliminary activity in mCRPC

The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.

October 23rd, 2026

KLK2-comPAS trial explores dual T-cell engagement in mCRPC

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

October 23rd, 2026

Darolutamide associated with less cognitive change than enzalutamide in prostate cancer

Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.

October 22nd, 2026

Engy Habashy, MD, on the role of androgens in GSM management

Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.

October 22nd, 2026

How PSMA-PET shapes staging and recurrence workup in prostate cancer

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

October 21st, 2026

Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC

Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.